RxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of “Buy” by Analysts

RxSight, Inc. (NASDAQ:RXST) has been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $61.63.

A number of equities research analysts have recently issued reports on RXST shares. Jefferies Financial Group started coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Wells Fargo & Company lowered their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Stifel Nicolaus dropped their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Finally, Oppenheimer decreased their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th.

Insiders Place Their Bets

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00. Following the completion of the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at $2,247,064.74. The trade was a 6.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Shweta Maniar sold 3,782 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the completion of the sale, the director now owns 10,902 shares in the company, valued at $500,183.76. The trade was a 25.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,702 shares of company stock valued at $3,059,197 over the last three months. Company insiders own 9.36% of the company’s stock.

Institutional Trading of RxSight

Several hedge funds have recently added to or reduced their stakes in RXST. Vanguard Group Inc. increased its stake in RxSight by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after buying an additional 40,500 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in RxSight by 1.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 60,908 shares of the company’s stock worth $3,143,000 after purchasing an additional 994 shares in the last quarter. California State Teachers Retirement System lifted its position in RxSight by 6.8% in the first quarter. California State Teachers Retirement System now owns 27,052 shares of the company’s stock worth $1,395,000 after purchasing an additional 1,733 shares during the period. RA Capital Management L.P. boosted its stake in RxSight by 1.1% during the 1st quarter. RA Capital Management L.P. now owns 3,442,825 shares of the company’s stock valued at $177,581,000 after purchasing an additional 38,540 shares in the last quarter. Finally, CWM LLC raised its position in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after purchasing an additional 371 shares during the period. Institutional investors own 78.78% of the company’s stock.

RxSight Trading Down 0.7 %

RXST stock opened at $46.06 on Wednesday. The company has a market capitalization of $1.86 billion, a P/E ratio of -55.49 and a beta of 1.19. The firm has a 50 day simple moving average of $49.20 and a 200-day simple moving average of $52.57. RxSight has a twelve month low of $28.88 and a twelve month high of $66.54.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.